e3-ligase
(5)
SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by proteins long considered undruggable. Powered by its proprietary RITE3 discovery platform - which pairs disease-causing target proteins with the most suitable of more than 600 human E3 ligases - SEED reprograms the cell's own ubiquitin-proteasome system to destroy harmful proteins rather than merely block them. Founded in 2020 by CEO Lan Huang and a group of protein-degradation pioneers including Nobel laureate Avram Hershko, the company advanced its lead oral RBM39 degrader ST-01156 into first-in-human Phase 1 trials in early 2026, with a broader pipeline spanning oncology, neurodegeneration, immunology and virology backed by partners Eli Lilly and Eisai.
Lan Huang
Lan Huang is a chemist turned biotech entrepreneur and the Co-Founder, Chairman and CEO of SEED Therapeutics, a New York clinical-stage company designing molecular glues that direct the cell's own disposal machinery to break down disease-driving proteins once considered undruggable. She earlier founded BeyondSpring Pharmaceuticals and took it public on NASDAQ. A UC Berkeley PhD who solved an early E3 ubiquitin ligase structure, she built SEED around targeted protein degradation with collaborators including Nobel laureate Avram Hershko, and secured partnerships with Eli Lilly and Eisai.
Plexium
Plexium is a San Diego precision medicine company designing small-molecule protein degraders - monovalent direct degraders and molecular glues - that switch off disease-driving proteins traditionally considered undruggable. Its DELTA Discovery platform runs ultra-high-throughput cell-based screening to find and optimize new degrader chemistry across cancer and neurological disease.
Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company in San Francisco pioneering targeted protein degradation - medicines that destroy disease-causing proteins rather than merely blocking them. Built on its DELigase discovery engine that harnesses the cell's ubiquitin-proteasome system and DNA-encoded library screening, Nurix is advancing a pipeline of degraders and degrader antibody conjugates for cancer and autoimmune disease, led by the BTK degrader bexobrutideg (NX-5948). The company is partnered with Roche, Sanofi, Gilead, and Pfizer (via Seagen) and trades on Nasdaq under NRIX.
Arthur T. Sands
Arthur T. Sands, M.D., Ph.D., is the President and CEO of Nurix Therapeutics, a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines. A co-founder of Lexicon Pharmaceuticals in 1995, he spent 19 years transforming that company from a research startup into a drug-development enterprise generating over $450 million in revenue. At Nurix, he leads efforts to deploy a proprietary DEL-AI platform - combining DNA-encoded libraries with machine learning - to discover and develop small-molecule degraders and degrader-antibody conjugates for cancer and inflammatory diseases. The company's lead asset, bexobrutideg (a BTK degrader), entered pivotal Phase 2 development in 2025 with an 83% objective response rate in relapsed CLL patients.